glp-1 agonist benefits Cardiovascular of glucagon-like peptide-1 receptor agonists GLP-1 Medications Clinic Near Me
Description
Clinical studies, such as the STEP trials, have shown that adults using semaglutide GLP-1 at the recommended dose (2.4 mg weekly) can lose an average of about 15% of their initial body weight over 68 weeks when combined with healthy lifestyle changes
safety disclaimers are clear on the website
GLP-1 = glucagon-like peptide-1
Moreover, an open-label trial tested exenatide, a GLP-1 RA, as a potential treatment for PD in a no-randomized, open-label study with 45 patients
They were also more likely to achieve clinically meaningful milestones like losing 5% or 10% of their starting weight
